BlackRock’s Metagenomi Therapeutics MGX Stock Holding History

BlackRock’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$307K	Buy	257,631 +27,497	+12%	+$36.8K	﹤0.01%	4697
2026 Q1	$308K	Buy	230,134 +5,993	+3%	+$9.31K	﹤0.01%	4643
2025 Q4	$363K	Buy	224,141 +690	+0.3%	+$1.49K	﹤0.01%	4571
2025 Q3	$530K	Sell	223,451 -72,913	-25%	-$148K	﹤0.01%	4443
2025 Q2	$439K	Sell	296,364 -1,247,709	-81%	-$1.95M	﹤0.01%	4479
2025 Q1	$2.1M	Buy	1,544,073 +99,125	+7%	+$236K	﹤0.01%	3983
2024 Q4	$5.22M	Buy	1,444,948 +1,009,286	+232%	+$2.44M	﹤0.01%	3710
2024 Q3	$945K	Buy	435,662 +15,420	+4%	+$53.5K	﹤0.01%	4186
2024 Q2	$1.71M	Buy	420,242 +305,918	+268%	+$2.1M	﹤0.01%	4009
2024 Q1	$1.21M	Buy	+114,324	New	+$1.31M	﹤0.01%	4150

Other funds holding MGX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock's MGX Position: Q2 2026 in Review

BlackRock increased its Metagenomi Therapeutics (MGX) stake by 12% in Q2 2026, buying an estimated $36.8K and bringing the position to 257,631 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #4697.

BlackRock first reported a position in MGX in Q1 2024 and has held it in 10 quarters since. The position peaked at $5.22M in Q4 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

BlackRock held 257,631 shares of Metagenomi Therapeutics worth $307K as of Q2 2026.
BlackRock bought 27,497 Metagenomi Therapeutics shares in Q2 2026, an estimated $36.8K.
Metagenomi Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4697 holding.
BlackRock first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 10 quarters since.
BlackRock's Metagenomi Therapeutics position peaked at $5.22M in Q4 2024.
43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.